FDA Summary Basis of Approval – Glatiramer Acetate Injection A206873

FDA Summary Basis of Approval – Glatiramer Acetate Injection A206873

Regular price $69.00 USD
Regular price Sale price $69.00 USD
Sale Sold out
Original Request: Dear Sir/Madam, We would like to request the Summary Basis of Approval for the Glatiramer Acetate Injection, 40 mg/mL application #A206873, approved on September 25, 2024. Detailed information about the application is provided below: Active Ingredient: GLATIRAMER ACETATE Proprietary Name: GLATIRAMER ACETATE Dosage Form; Route of Administration: INJECTABLE; SUBCUTANEOUS Strength: 40MG/ML Application Number: A206873
  • Status: Pending Fast-Track Request
  • Delivery: Approximately 1 to 2 weeks when the FOIA office is operating at regular capacity

NOTE: This document is not currently in our library. Upon purchase, we will request the document from the FDA FOIA office. Learn more about Fast-Track Requests here.

View full details